JPS61194017A - 抗血栓剤 - Google Patents
抗血栓剤Info
- Publication number
- JPS61194017A JPS61194017A JP60035486A JP3548685A JPS61194017A JP S61194017 A JPS61194017 A JP S61194017A JP 60035486 A JP60035486 A JP 60035486A JP 3548685 A JP3548685 A JP 3548685A JP S61194017 A JPS61194017 A JP S61194017A
- Authority
- JP
- Japan
- Prior art keywords
- lemongrass oil
- lemongrass
- aggregation
- aspirin
- citral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003146 anticoagulant agent Substances 0.000 title claims description 13
- 229940127217 antithrombotic drug Drugs 0.000 title 1
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 25
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims abstract description 17
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 claims abstract description 14
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940088601 alpha-terpineol Drugs 0.000 claims abstract description 14
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940043350 citral Drugs 0.000 claims abstract description 13
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 claims abstract description 12
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000000484 citronellol Nutrition 0.000 claims abstract description 12
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims abstract description 11
- 239000005792 Geraniol Substances 0.000 claims abstract description 11
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 claims abstract description 11
- 229940113087 geraniol Drugs 0.000 claims abstract description 11
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims description 21
- 229960004676 antithrombotic agent Drugs 0.000 claims description 11
- 239000001941 cymbopogon citratus dc and cymbopogon flexuosus oil Substances 0.000 abstract description 55
- 230000000694 effects Effects 0.000 abstract description 19
- 240000004784 Cymbopogon citratus Species 0.000 abstract description 13
- 235000017897 Cymbopogon citratus Nutrition 0.000 abstract description 13
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 208000006673 asthma Diseases 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 3
- 210000001772 blood platelet Anatomy 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000035943 smell Effects 0.000 abstract 1
- 238000001256 steam distillation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 description 28
- 238000004220 aggregation Methods 0.000 description 28
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 25
- 229960001138 acetylsalicylic acid Drugs 0.000 description 25
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 9
- 229940114079 arachidonic acid Drugs 0.000 description 9
- 235000021342 arachidonic acid Nutrition 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 229940127218 antiplatelet drug Drugs 0.000 description 6
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 3
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000019645 odor Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- 231100000216 vascular lesion Toxicity 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100113485 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chs-3 gene Proteins 0.000 description 1
- 206010073391 Platelet dysfunction Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000010446 mirabilite Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60035486A JPS61194017A (ja) | 1985-02-25 | 1985-02-25 | 抗血栓剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60035486A JPS61194017A (ja) | 1985-02-25 | 1985-02-25 | 抗血栓剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61194017A true JPS61194017A (ja) | 1986-08-28 |
| JPS6411616B2 JPS6411616B2 (OSRAM) | 1989-02-27 |
Family
ID=12443076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60035486A Granted JPS61194017A (ja) | 1985-02-25 | 1985-02-25 | 抗血栓剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61194017A (OSRAM) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05246870A (ja) * | 1992-03-04 | 1993-09-24 | Yoshihide Hagiwara | ヒト血小板凝集阻害剤 |
| JP2001278802A (ja) * | 2000-03-30 | 2001-10-10 | Hiroyuki Sumi | 血栓予防剤 |
| JP2010001285A (ja) * | 2008-05-21 | 2010-01-07 | Daiichi Sankyo Healthcare Co Ltd | 内服用虫よけ剤 |
| CN118987008A (zh) * | 2024-08-09 | 2024-11-22 | 皖西学院 | 调节血小板聚集的组合物、以血小板衍生生长因子受体α为靶点的筛选方法及应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012051906A (ja) * | 2011-10-05 | 2012-03-15 | Ichimaru Pharcos Co Ltd | トリプシン阻害剤 |
-
1985
- 1985-02-25 JP JP60035486A patent/JPS61194017A/ja active Granted
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05246870A (ja) * | 1992-03-04 | 1993-09-24 | Yoshihide Hagiwara | ヒト血小板凝集阻害剤 |
| JP2001278802A (ja) * | 2000-03-30 | 2001-10-10 | Hiroyuki Sumi | 血栓予防剤 |
| JP2010001285A (ja) * | 2008-05-21 | 2010-01-07 | Daiichi Sankyo Healthcare Co Ltd | 内服用虫よけ剤 |
| JP2014043457A (ja) * | 2008-05-21 | 2014-03-13 | Lotte Co Ltd | 内服用虫よけ剤 |
| CN118987008A (zh) * | 2024-08-09 | 2024-11-22 | 皖西学院 | 调节血小板聚集的组合物、以血小板衍生生长因子受体α为靶点的筛选方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6411616B2 (OSRAM) | 1989-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bordia et al. | Effect of the essential oils of garlic and onion on alimentary hyperlipemia | |
| CA2473874C (en) | A composition for treating neurocerebrovascular disorders | |
| Arora et al. | The long-term use of garlic in ischemic heart disease An appraisal | |
| Zubairu et al. | Effect of Anacardium occidentale fruit juice extract on haematological parameters and spleen of paracetamol induced injury in albino rats | |
| Homburger et al. | The carcinogenicity of essential oils, flavors, and spices: a review | |
| JP2015163644A (ja) | 豆抽出物を含有する血液循環改善及び血管健康増進用組成物 | |
| GB1580444A (en) | Pharmaceutical compositions | |
| US20040033277A1 (en) | Herbal medicaments for the treatment of neurocerebrovascular disorders | |
| JPS61171427A (ja) | 血栓等予防物質 | |
| JP4813418B2 (ja) | パッションフルーツの抽出物を用いる炎症障害の治療方法 | |
| Sharma et al. | Ocimum: The holy basil against cardiac anomalies | |
| Grotenhermen | Cannabis-associated arteritis | |
| US4061738A (en) | Process for reducing platelet adhesiveness | |
| JPS6411616B2 (OSRAM) | ||
| Thomas et al. | Effects of methanolic seed extract of Telfairia occidentalis on blood coagulation in Albino rats | |
| JP3213741B2 (ja) | アルキルサルファイドの脱臭法 | |
| Friend | Aspirin: the unique drug | |
| JPS6320384A (ja) | 抗酸化用組成物 | |
| JPS63203682A (ja) | 新規フラボノイド配糖体及びその製造方法 | |
| JP2006028074A (ja) | 血小板凝集抑制組成物 | |
| JP7339698B2 (ja) | 野せり抽出物および抗血栓剤を含む抗血栓用組成物 | |
| JP5578822B2 (ja) | アセチルコリンエステラーゼ阻害剤 | |
| KR960007924B1 (ko) | 인삼의 인지질 성분을 함유하는 항혈소판제 | |
| Yamada et al. | Inhibition of platelet aggregation by a new agent, 2, 2′-dithiobis-(N-2-hydroxypropyl benzamide)(KF4939) | |
| JPH04178324A (ja) | カルシウム拮抗剤 |